Health ❯ Pharmaceuticals

Obesity Treatment

Wegovy Weight Loss Drugs Drug Development Weight-loss Drugs GLP-1 Drugs Diabetes Management Semaglutide Clinical Trials Weight Loss Medications Weight Management Drug Efficacy Weight Loss GLP-1 Receptor Agonists Market Competition GLP-1 Analogues Novo Nordisk Anti-Obesity Drugs Alzheimer's Treatment Diabetes Treatment GLP-1/GIP Medications Eli Lilly Drug Injectable Drugs Retatrutide Drug Sales Drug Market GLP-1RA Weight Loss Solutions Injectable Medications GLP-1 Medicines Oral GLP-1 Molecule AI Integration Weight-loss Medications

Lilly Sues Six U.S. Firms Over Black‑Market Sales of Experimental Drug Retatrutide

The filings mark a broad effort to enlist courts, regulators and payment and shipping firms to stop unapproved sales that Lilly says put patients at risk

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs